Bepranemab

贝瑞奈单抗

Report date: 2025/06/07 20:00:15

Base Information

Drug NameBepranemab
Drug Alias NameUCB-0107RG6416
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionMicrotubule-associated protein tau inhibitors
TargetsMicrotubule-associated protein tau
Therapy Area/IndicationsAlzheimer DiseaseSupranuclear Palsy, Progressive
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[10] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesUcb
China Registration ClassN/A

Develop Information

Active CompaniesUcb Biopharma SrlF. Hoffmann-La Roche Ltd
Inactive CompaniesUcb Biopharma SprlGenentech Inc
Active IndicationsAlzheimer DiseaseSupranuclear Palsy, Progressive
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A